A key first-line treatment option for many patients with symptomatic anemia associated with lower-risk MDS is erythropoiesis-stimulating agents (ESAs) (e.g., epoetin alpha or darbepoetin alpha), which may also be combined with granulocyte colony–stimulating factor (G-CSF) [8]. This evidence concerns the gene CSF3 and myelodysplastic syndrome.